ClearPoint Neuro, Inc. (CLPT) Earnings
ClearPoint Neuro, Inc. is expected to report next earnings on August 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.27. CLPT has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -22.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.28 | $-0.32 | -14.3% | $12M | +1.3% |
| Mar 17, 2026 | $-0.20 | $-0.27 | -37.5% | $10M | +3.6% |
| Nov 6, 2025 | $-0.20 | $-0.21 | -5.0% | $9M | -14.8% |
| Feb 26, 2025 | $-0.15 | $-0.20 | -33.3% | $8M | -5.6% |
| Nov 7, 2024 | $-0.17 | $-0.18 | -5.9% | $8M | +4.4% |
| Mar 12, 2024 | $-0.22 | $-0.19 | +13.6% | $7M | +4.3% |
| Nov 9, 2023 | $-0.25 | $-0.20 | +20.0% | $6M | -9.3% |
| May 11, 2023 | $-0.18 | $-0.23 | -27.8% | $5M | +6.5% |
| Mar 1, 2023 | $-0.22 | $-0.18 | +18.2% | $5M | -0.5% |
| Aug 9, 2022 | $-0.18 | $-0.18 | +0.0% | $5M | +2.3% |
| Mar 1, 2022 | $-0.19 | $-0.19 | +0.0% | $4M | -0.4% |
| Mar 4, 2021 | $-0.13 | $-0.09 | +30.8% | $4M | +12.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 13, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Overall Strategic Positioning - ClearPoint is a hybrid device biotech enabling company focused on building a complete minimally invasive neuroecosystem for brain delivery of cell and gene therapies, addressing a large unmet medical need for neurologic disorders. - As of Q1 2026, the company has over 60 active biopharma partners, 25+ ongoing clinical trials across 15+ disease indications, and 10 partner programs under FDA expedited review. - Post-merger integration of the ERAS/IRIS acquisition was mostly completed in Q1 2026, with most one-time integration costs now incurred. Total global active sites using ClearPoint technology exceed 175, with a target of surpassing 200 by the end of 2026. • Four Growth Pillar Progress - Pre-commercial biologics and drug delivery: Construction of the new ClearPoint Advanced Laboratories (CAL) facility in Torrey Pines, California is ongoing. Despite construction-related downtime in March, the team completed multiple first-of-its-kind new route of administration testing for partners. The Aeroflow product line integration is underway, with ongoing partner discussions and planned updates later in 2026. - Neuronavigation and robotics: The 3.x platform launch continues in the U.S., with the first Canadian clinical cases expected shortly. The prototype ClearPoint robotic platform (built on the KUKA LBR medrobotic arm, leveraging 15+ years of proprietary cranial navigation software development) completed its first preclinical drug delivery case with better-than-expected results, and will be available to partners for preclinical studies at CAL. - Laser therapy and access: The Velocity Alpha MR high-speed surgical drill received FDA clearance and CE marking in Q1 2026, enabling global availability and expected procedural time reductions. The PRISM laser system continues to see strong adoption, with expanded labeling for both 3.0 and 1.5 Tesla scanners opening a larger customer base. - Neurocritical care and active CSF exchange: This new segment from the ERAS acquisition adds flexible indwelling catheters to ClearPoint's drug delivery portfolio, a capability the company previously lacked. Commercial team integration and cross-training is complete, with multiple identified revenue and cost synergies. Management expects the Aeroflow business could be cash neutral for ClearPoint as early as 2027.
Guidance
• Full year 2026 total revenue guidance is maintained at $52 million to $56 million, with all four core growth segments expected to deliver double-digit growth in 2026 (this excludes any revenue from commercial cell and gene therapy launches, which are not expected until after 2026 pending global approvals). • Operational cash burn is expected to decrease in subsequent quarters as ERAS integration wraps up; Q1 2026 cash burn came in at $8 million, in line with budget, and Q1 is historically the highest burn quarter annually for the company. • The CAL facility is expected to reach full operational capacity by Q1 2027, with incremental capacity additions through the end of 2026. Sequential quarter-over-quarter revenue growth is expected for the remainder of 2026. • Aeroflow is expected to represent 20% to 25% of total annual revenue in 2026, and the segment is targeting cash neutrality by 2027. Gross margins for Aeroflow are expected to expand as the business scales and facility consolidation is completed.
Segment performance
ClearPoint Neuro reported total Q1 2026 revenue of $12.1 million, a 43% increase year-over-year (YoY) from $8.5 million in Q1 2025. There are three core revenue segments: 1. Biologics and drug delivery: Revenue increased 2% YoY to $4.8 million, representing 39.7% of total Q1 2026 revenue. The small gain came from a $0.1 million increase in product revenue, while service revenue was flat YoY. 2. Neurosurgery, navigation, and therapy: Revenue grew to $5.9 million, including $2.1 million in Aeroflow disposable revenue, representing 48.8% of total Q1 2026 revenue. Growth was driven by an expanded installed base, full market release of the PRISM laser system, and the ICT solution. 3. Capital equipment and software: Revenue increased 177% YoY to $1.4 million from $0.5 million in Q1 2025, representing 11.6% of total Q1 2026 revenue. Growth came from increased sales of ClearPoint Navigation System units, PRISM laser units, and Aeroflow control units. Gross margin for Q1 2026 was 64%, up 4% YoY, driven by lower excess and obsolete inventory reserves.
Risks & headwinds
• Construction delays and capacity underutilization at the new CAL facility could delay preclinical study bookings and push revenue into future periods, creating variability that drives results toward the lower end of the 2026 guidance range. • Recent FDA leadership changes and ongoing regulatory uncertainty, particularly for rare disease cell and gene therapy programs, could create delays in trial approvals and review timelines for the company's partners. • Transitioning Aeroflow to direct distribution outside of the U.S. has created a temporary growth lag in international markets for the product line. • The company continues to operate with negative operating cash flow; while burn is expected to decrease, it will remain a factor as the business invests in global expansion and new facility buildout. As of March 31, 2026, the company held $35.6 million in cash and cash equivalents, down from $45.9 million at the end of 2025. • Gross margin can fluctuate quarter-over-quarter, and the 64% Q1 2026 gross margin is not guaranteed to be sustained in future periods.
Analyst Q&A
Q: What impact have recent FDA leadership changes had on ClearPoint's regulatory interactions, and what is the status of the company's work with the Neurona partner that is being acquired by UCB? /
A: There has been no negative impact or disruption to interactions on the device side of the business, where pre-submission meetings have continued smoothly with a largely intact team. For biologic/combination device programs, there is existing widespread industry uncertainty amid ongoing leadership appointments for CBER and FDA overall, with the biggest practical impact on rare disease programs that struggle to enroll large sham-controlled trials; this uncertainty has not affected programs for higher-prevalence disorders that always planned for pivotal phase 3 trials. The Neurona team remains fully intact after the UCB acquisition, and ClearPoint will continue supporting the Neurona asset's ongoing phase 3 pivotal trial as planned, with an existing long-standing positive relationship with UCB.
Q: What factors will drive whether 2026 full-year revenue lands at the low or high end of the guided range? /
A: The primary variable is the timing of preclinical study bookings at the new CAL facility, which is currently significantly sub-scale. Only ~20% of the facility's total revenue-generating capacity was available in Q1 2026 due to phased construction, with full buildout expected by Q1 2027. Incremental capacity will be added gradually through the second half of 2026, so the timing of new study bookings will directly determine where full-year revenue falls within the guided range.
Q: Is the Q1 2026 64% gross margin sustainable, and what is the expected sustained operating expense run rate after one-time Q1 integration costs? /
A: Gross margin will fluctuate quarter-to-quarter, so the Q1 level is not guaranteed to hold in future periods. Multiple cost synergy opportunities from the ERAS acquisition are being realized, including consolidation of manufacturing facilities (the empty former Aeroflow San Diego facility is being subleased), redundant vendor elimination, better raw material pricing from higher volume, and reduced travel costs for sales and clinical teams from combined portfolio volume. These synergies will support expanding margins and controlled operating expenses as the business scales.
Q: Does ClearPoint already have all the assets needed to hit its long-term $500 million revenue target, and will inorganic acquisitions be needed to accelerate reaching that goal? /
A: ClearPoint already has all core portfolio pieces in place to reach the target, with only incremental refinement and execution needed. A cleared robotic platform is the last major development milestone, which is progressing via preclinical testing and is not dependent on external invention or luck. There are very few relevant inorganic acquisition targets that fit ClearPoint's focused strategy of staying within cranial drug delivery (avoiding higher-complexity adjacent areas like neurovascular), so the company does not need inorganic acquisitions to reach the long-term revenue target and expects to get there via organic scaling driven by growing adoption of cell and gene therapies and existing product lines.